A Phase I Trial of Dabrafenib (BRAFi) and Pazopanib in Patients With BRAF-mutated Advanced Malignant Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 11 May 2017
At a glance
- Drugs Dabrafenib (Primary) ; Pazopanib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 12 Sep 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Mar 2017.
- 19 May 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
- 21 Nov 2014 Interim results presented at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.